Reading a Tumor's genetic signature to outsmart head and neck cancer
NCT ID NCT06725342
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study analyzes DNA and RNA from stored tumor samples of 401 people with head and neck squamous cell carcinoma. The goal is to classify each tumor by its genetic mutations and immune activity, potentially pointing toward which treatments—such as immunotherapy—might work best. No new drugs are being tested; instead, researchers aim to build a molecular roadmap for smarter treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this approach could help doctors select the most effective treatments for each patient based on their tumor's genetic and immune profile.
- What could go wrong
- This is an observational, lab-based study, not a treatment trial. The classification system may not translate into better outcomes until tested in future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
401 people
The number who actually took part.
- Started
-
Dec 2014
- Finished
-
Mar 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with locally advanced squamous cell carcinoma of the head and neck who were treated with concurrent chemoradiotherapy (CCRT) with or without induction chemotherapy (IC) or radical surgery +/- radiotherapy for laryngeal tumors.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: -Patients with locally advanced squamous cell carcinoma of the head and neck who were treated with concurrent chemoradiotherapy (CCRT) with or without induction chemotherapy (IC) or radical surgery +/- radiotherapy for laryngeal tumors. Exclusion Criteria: * Age \<18 years old * Non-squamous cell carcinomas of the head and neck.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head and neck squamous cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer aims to light up hidden cancer targets
- Can immunotherapy before surgery stop early oral cancer from returning?
- Can a glowing dye show surgeons where head and neck tumors end?
- Can a Four-Part combo before surgery wipe out head and neck tumors?
- Can a new drug shrink advanced solid tumors?
- Can steroid shots shield salivary glands from radiation damage?